tldrdailynews.com logo

Pelacarsen's big failure rocks cardiology hopes

1 min read
Source: The New York Times
Pelacarsen's big failure rocks cardiology hopes
Photo: The New York Times
TL;DR Summary

Novartis announced that pelacarsen, an experimental drug designed to lower lipoprotein(a) and reduce risk of heart attack, stroke, and cardiovascular death, failed in a large clinical trial, delivering a shock to the field of cardiology and ending hopes for a new era in heart-disease prevention.

Topics:business#cardiovascular-disease#clinical-trial#health#lpa#novartis#pelacarsen
Share this article
  1. Another Heart Drug Fails, Shocking Cardiologists  The New York Times
  2. Novartis’ experimental cardiovascular drug fails a pivotal study  STAT
  3. Novartis Drug Fails Key Test for New Heart Disease Approach  Bloomberg.com
  4. Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)  Business Wire
  5. Novartis announces Lp(a)HORIZON Phase III topline results  GlobeNewswire

Reading Insights

Total Reads

1

Unique Readers

4

Time Saved

14 min

vs 15 min read

Condensed

98%

2,804 → 45 words

Want the full story? Read the original article

Read on The New York Times